This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.




Text Version  RSS  Subscribe  Unsubscribe  Archive  Media Kit October 03, 2014
Home    About AST    Education    Meetings & Events    Public Policy    Contact Us  

 

SOCIETY NEWS

Submit your nomination for 2015 AST Achievement Awards
AST
The American Society of Transplantation (AST) is now accepting nominations for the 2015 AST Achievement Awards. Each year, the AST sponsors a variety of Achievement Awards in recognition of our members’ achievements and contributions to the field of transplantation. All nominations must be submitted by Monday, Nov. 17, 2014. Click here for more details and to submit your nomination.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article




2015 Call for AST Board nominations
AST
Dr. Daniel Salomon, Chair of the Governance Committee, invites AST members to submit nominations for qualified individuals to serve on the AST Board of Directors. Open positions on the AST Board of Directors include the President-Elect, Secretary (2 year term), and three Councilors-at-Large (three-year terms). The term of service begins with the rotation of the Board at the Town Hall that will be held during the 2015 American Transplant Congress in Philadelphia, Pennsylvania. Completed nominations must be submitted to the AST National Office by 5 p.m. EST on Friday, Nov. 14, 2014. Review the criteria, or submit a nomination.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


UPCOMING EVENTS IN TRANSPLANTATION


There is still time to register for the ESOT + AST Joint Meeting
AST
Personalized Transplantation: From New Diagnostics to New Therapeutics
Oct. 17-19, 2014
Madrid, Spain

Long-term graft and patient survival are the key issues in transplantation. Outcomes are affected by individual immune risk and co-morbidities, as well as gender and race. The time is now to focus on improving outcomes through personalized medicine and finding the optimal combination of immunosuppressive drugs in the right dose for each patient. Register now to attend this focused meeting on personalized transplantation. Join the ESOT and AST in beautiful Madrid, Spain as together we explore:
  • New Options to Improve Immunosuppressive Therapy
    Belatacept, Anti CD40 trial (ASKP1240), Anti- IL-6 and Tacrolimus formulations
  • Novel Diagnostics
    Donor DNA - Biomarker of Graft Injury, In vivo Live Imaging of the Immune Response and Tolerance Profile
  • Novel Targets for Immunosuppression
    B-cells, Plasma Cells and Complement
  • Personalized Medicine: Technique and Technology
    Sequencing for TCR Repertoire, Pharmacogenetics, Epigenetics and Mixed Chimerism
  • Cellular Strategies to Optimize Long Term Outcomes
    T-regs, Mesenchymal Cells, Facilitator Cells
Click here to learn more about this enlightening meeting, or view the full program.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Submit your basic, clinical, and translational abstracts by Oct. 31
The Cutting Edge of Transplantation
Immunity and Inflammation: Engineering Cell, Gene, and Drug Therapies

AST
Feb. 5-7, 2015
Sheraton Wild Horse Pass – Chandler, Arizona

The AST is now accepting abstracts for the Cutting Edge of Transplantation meeting. Don’t miss out on the opportunity to share your research with experts in transplantation. Submit your basic, clinical or translational abstract by Oct. 31. The AST will award a limited number of Young Innovator Award travel grants to the highest scoring abstracts submitted by emerging professionals in transplantation.

Click here to register for CEOT 2015 and take advantage of early registration discounted rates! Or, learn more about this engaging meeting and view the preliminary program here.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


COMMITMENT TO CARE
Raptor's mission is to develop and commercialize life-altering therapeutics that treat rare, debilitating, and often fatal diseases.
LEARN MORE
Advertise here!

To find out how to feature your company in the AST eNewsletter and other advertising opportunities, Contact Tom Crist at 972-402-7724.
MORE


TRANSPLANT NEWS


Demethylation of the TSDR is a marker of squamous cell carcinoma in transplant recipients
American Journal of Transplantation
Malignancy is an important cause of death in transplant recipients. Cutaneous squamous cell carcinoma (cSCC) causes significant morbidity and mortality as 30 percent of transplant recipients will develop cSCC within 10 years of transplantation. Previously we have shown that high numbers of regulatory T cells (Tregs) are associated with the development of cSCC in kidney transplant recipients (KTRs). Demethylation analysis of the Treg-specific demethylated region (TSDR) provides a more accurate association with cSCC risk after transplantation.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


PRODUCT SHOWCASE
  UCLA Immunogenetics Center

The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE
 


Toward a better liver graft allocation that accounts for candidates with and without hepatocellular carcinoma
American Journal of Transplantation
In some countries where the Model for End-Stage Liver Disease (MELD) score is used for graft allocation, selected patients with hepatocellular carcinoma (HCC) receive a fixed number of exception points at listing, and increasing priority on the list by accruing additional exception points at regular time intervals. This system originally aimed at balancing the risks of HCC patients of developing contraindications and of non-HCC patients of dying before transplantation, is not ideal because it appears to offer an advantage to HCC patients, regardless of tumor characteristics and response to loco-regional treatment.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Kidney and liver transplantation in children with fibrocystic liver–kidney disease: Data from the US Scientific Registry of Transplant Recipients: 1990–2010
Pediatric Transplantation
The natural history and survival of children with fibrocystic liver–kidney disease undergoing solid organ transplantation have infrequently been described. We report outcomes in a cohort of US children with fibrocystic liver–kidney disease receiving solid organ transplants over 20 years. Retrospective cohort study of pediatric transplant recipients with diagnoses of fibrocystic liver–kidney disease from 1/1990 to 3/2010, using data from the SRTR.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Myocyte growth, repair, and oxidative stress following pediatric heart transplantation
Pediatric Transplantation
Cardiac remodeling is associated with plasma biomarkers of fibrinogenesis, inflammation, and oxidative stress, and upregulation of mitogenic, pro-fibrotic, and apoptotic signaling pathways. Our primary objective was to evaluate biomarker and subcellular myocardial changes in pediatric heart transplant recipients. Fifty-two-week prospective, randomized (tacrolimus, Tac, vs. cyclosporine, CsA), open-label, parallel group study.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Survival benefit of repeat liver transplantation in the United States: A Serial MELD analysis by hepatitis C status and donor risk index
American Journal of Transplantation
Survival benefit (SB) for first liver transplantation (LT) is favorable at Model for End-Stage Liver Disease (MELD) ≥15. Herein, we identify the MELD threshold for SB from repeat liver transplantation (ReLT) by recipient hepatitis C virus (HCV) status and donor risk index (DRI). We analyzed lab MELD scores in new United Network for Organ Sharing registrants for ReLT from March 2002 to January 2010.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Transmission of LDLR mutation from donor through liver transplantation resulting in hypercholesterolemia in the recipient
American Journal of Transplantation
Donor-transmitted disease in organ transplantation is uncommon, but possible. The LDL receptor (LDLR), a key regulator of lipoprotein metabolism, is abundant in the liver. Mutations in the LDLR gene, leading to reduced LDLR activity, are the main cause for familial hypercholesterolemia (FH). The estimated prevalence of FH is 1/200–1/500 in the population indicating that there are 14–34 million individuals with FH worldwide. We describe a patient who developed severe hypercholesterolemia after liver transplantation (LT).
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Neutrophil-to-lymphocyte ratio predicts mortality in patients listed for liver transplantation
Liver International
In the absence of overt infection, the systemic inflammatory response is increasingly recognised as a pathogenetic factor in the circulatory dysfunction of advanced cirrhosis. Our aim was to determine whether the neutrophil-to-lymphocyte ratio, a marker of systemic inflammation, is predictive of mortality in patients with end stage cirrhosis listed for liver transplantation.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


TRENDING ARTICLES
Missed last week's issue? See which articles your colleagues read most.

    Toward a better liver graft allocation that accounts for candidates with and without hepatocellular carcinoma (American Journal of Transplantation)
Outcome of latent tuberculosis infection in solid organ transplant recipients over a 10-year period (Transplantation)
An analysis of pancreas transplantation outcomes based on age groupings – an update of the UNOS database (Clinical Transplantation)
Porcine acellular dermal matrix for delayed abdominal wall closure after pediatric liver transplantation (Pediatric Transplantation)

Don't be left behind. Click here to see what else you missed.


Risk factors for early and late biliary complications in pediatric liver transplantation
Pediatric Transplantation
BC are a common source of morbidity after pediatric LT. Knowledge about risk factors may help to reduce their incidence. Retrospective analysis of BC in 116 pediatric patients (123 LT) (single institution, 05/1990–12/2011, medium follow-up 7.9 year). One-, five-, and 10-year survival was 91.1 percent, no patient died of BC. Prevalence and risk factors for anastomotic and intrahepatic BC were examined.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Influence of recipient age on deceased donor kidney transplant outcomes in the expanded criteria donor era
Clinical Transplantation
This study performed a retrospective single center review of 884 deceased donor (DD) kidney transplants (KTs) in patients (pts) aged ≥40.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 



AST eNews

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Julie Bernhard, Executive Editor, 469.420.2647  
Contribute news


This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

Recent issues
Sept. 26, 2014
Sept. 19, 2014
Sept. 12, 2014
Sept. 5, 2014






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063